
|Videos|November 9, 2022
Dr. Albala on financial implications of emergence of PSMA-PET imaging
Author(s)Urology Times staff
“What’s important is that we get these studies approved so that our patients aren’t suffering any further economic burdens by having this new type of imaging being put forward,” says David Albala, MD.
Advertisement
In this video, urologist David Albala, MD, explains financial issues related to the emergence of PSMA-PET imaging as a critical component of the prostate cancer management paradigm. Albala is discussing PSMA-PET imaging during the CME program at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA reports increased demand, supply efforts for estradiol transdermal patches
2
The UroOnc Minute: Perioperative Intravesical Chemotherapy at Nephroureterectomy, With Surena F. Matin, MD, FACS
3
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
4
NeoBLAST trial tests active surveillance after complete response in MIBC
5











